RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC 50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC 50 s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC 50 of 1.1 μM In Vitro RIPK3-IN-1 (Compound 18) also inhibits ABL, BRAF/V599E, MAP4K3, and SRC with IC 50 s of 0.37, 0.15, 0.012, and 0.075 μM, respectively. Necroptosis is a programmed form of cell death and has been associated with a variety of diseases, including ischemia reperfusion injury, neurodegenerative disorders, pancreatic cancer, and autoimmune diseases such as inflammatory bowel disease (IBD). Upon stimulation of death receptors (such as the family of TNF receptors), signaling can initiate a necroptotic cell death process. This involves formation of a necrosome, which includes receptor interacting protein kinases 1 and 3 (RIPK1, RIPK3) in a cytosolic complex. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 9.1 nM (RIPK3), 5.5 μM (RIPK1), >10 μM (RIPK2)